FoRx Therapeutics appoints Dr. Jens Wurthner, PhD, as Chief Medical Officer and reports progress toward IND submission by mid ...
"When I was navigating going into the field of medicine there weren't a lot of people who looked like me and that makes it challenging so I wanted to be able to be that representation for them that I ...
Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and ...
Industry veteran in clinical development of oncology therapeutics, Dr. Jens Wurthner, PhD, joins as Chief Medical Officer Lead development candidate, FORX-428, a PARG inhibitor for solid tumors ...
BIO 300 will be the subject of a presentation at a U.S. industry, national security, and healthcare forum on February 27th, 2025.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback